PA
Pathos AI
United States · Biotech · AI
Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.
Product
Pathos AI develops its own portfolio of cancer therapies using Foundry, an AI platform that combines clinical, genomic and biological evidence to guide development decisions.
The New York company uses the platform to identify assets, refine patient selection and adapt clinical programs. Its pipeline spans prostate cancer, multiple myeloma and other solid tumors. Bristol Myers Squibb led its $237 million Series E in October 2026.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series E | $237M | Bristol Myers Squibb — Lead |